Allogeneic stem cell transplantation improves survival in
patients with AML characterized by a high allelic ratio of
mutant FLT3-ITD

J 2016

Allogeneic stem cell transplantation improves survival in patients with AML characterized by a high allelic ratio of mutant FLT3-ITD

HO, A. D.; J. SCHETELIG; T. BOCHTLER; M. SCHAICH; K. SCHÄFER-ECKART et al.

Základní údaje

Originální název

Allogeneic stem cell transplantation improves survival in patients with AML characterized by a high allelic ratio of mutant FLT3-ITD

Autoři

Vydání

Biology of Blood and Marrow Transplantation, New York, Elsevier Science INC, 2016, 1083-8791

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 4.704

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/16:00089168

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

allogeneic transplantation; acute myeloid leukemia; FLT3-ITD; NPM1-mutation

Štítky

EL OK, podil

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 2. 8. 2016 14:07, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Allogeneic transplantation (alloHCT) as post-remission therapy in patients with FLT3-ITD-positive intermediate-risk acute myeloid leukemia (AML) remains controversial. FLT3-ITD mutations are heterogeneous with respect to allelic ratio, location and length of the insertion, with a high mutant-to-wildtype ratio being consistently associated with inferior prognosis. We retrospectively analyzed the role of alloHCT in first remission in relationship to the allelic ratio and presence or absence of nucleophosmin 1 mutations (NPM1) in the SAL-AML2003 trial. FLT3-ITD mutations were detected in 209 patients and concomitant NPM1-mutations in 148 patients. Applying a pre-defined cutoff ratio of 0.8, AML was grouped into high- and low-ratio FLT3-ITD AML (HRFLT3-ITD and LRFLT3-ITD). Sixty-one patients (29%) were transplanted in first remission. Overall survival (OS) (HR 0.3, 95%CI 0.16 to 0.7, p=.004) and event-free survival (EFS) (HR 0.4, 95%CI 0.16 to 0.9, p=.02) were significantly increased in patients with HRFLT3-ITD AML who received alloHCT as consolidation treatment compared to patients who received consolidation chemotherapy. Patients with LRFLT3-ITD AML and wildtype NPM1 who received alloHCT in first remission had increased OS (HR 0.3; 95%CI 0.1 - 0.8, p=.02) and EFS (HR 0.2; 95%CI 0.1 - 0.8, p=.02) while alloHCT in first remission did not have a significant impact on OS and EFS in patients with LRFLT3-ITD AML and concomitant NPM1-mutation. In conclusion, our results provide additional evidence that alloHCT in first remission improves EFS and OS in patients with HRFLT3-ITD AML and in patients with LRFLT3-ITD AML and wildtype NPM.

Přiložené soubory

EL_1316948.pdf

Požádat o autorskou verzi souboru

Citovat

HO, A. D.; J. SCHETELIG; T. BOCHTLER; M. SCHAICH; K. SCHÄFER-ECKART; M. HÄNEL; W. RÖSLER; H. EINSELE; M. KAUFMANN; H. SERVE; W. E. BERDEL; M. STELLJES; Jiří MAYER; A. REICHLE; C. D. BALDUS; N. SCHMITZ; M. KRAMER; C. RÖLLIG; M. BORNHÄUSER; C. THIEDE a G. EHNINGER. Allogeneic stem cell transplantation improves survival in patients with AML characterized by a high allelic ratio of mutant FLT3-ITD. Biology of Blood and Marrow Transplantation. New York: Elsevier Science INC, 2016, roč. 22, č. 3, s. 462-469. ISSN 1083-8791. Dostupné z: https://doi.org/10.1016/j.bbmt.2015.10.023.

@article{1316948,
   author = {Ho, A. D. and Schetelig, J. and Bochtler, T. and Schaich, M. and SchäferandEckart, K. and Hänel, M. and Rösler, W. and Einsele, H. and Kaufmann, M. and Serve, H. and Berdel, W. E. and Stelljes, M. and Mayer, Jiří and Reichle, A. and Baldus, C. D. and Schmitz, N. and Kramer, M. and Röllig, C. and Bornhäuser, M. and Thiede, C. and Ehninger, G.},
   article_location = {New York},
   article_number = {3},
   doi = {https://doi.org/10.1016/j.bbmt.2015.10.023},
   keywords = {allogeneic transplantation; acute myeloid leukemia; FLT3-ITD; NPM1-mutation},
   language = {eng},
   issn = {1083-8791},
   journal = {Biology of Blood and Marrow Transplantation},
   title = {Allogeneic stem cell transplantation improves survival in patients with AML characterized by a high allelic ratio of mutant FLT3-ITD},
   volume = {22},
   year = {2016}
}

TY  - JOUR
ID  - 1316948
AU  - Ho, A. D. - Schetelig, J. - Bochtler, T. - Schaich, M. - Schäfer-Eckart, K. - Hänel, M. - Rösler, W. - Einsele, H. - Kaufmann, M. - Serve, H. - Berdel, W. E. - Stelljes, M. - Mayer, Jiří - Reichle, A. - Baldus, C. D. - Schmitz, N. - Kramer, M. - Röllig, C. - Bornhäuser, M. - Thiede, C. - Ehninger, G.
PY  - 2016
TI  - Allogeneic stem cell transplantation improves survival in patients with AML characterized by a high allelic ratio of mutant FLT3-ITD
JF  - Biology of Blood and Marrow Transplantation
VL  - 22
IS  - 3
SP  - 462-469
EP  - 462-469
PB  - Elsevier Science INC
SN  - 10838791
KW  - allogeneic transplantation
KW  - acute myeloid leukemia
KW  - FLT3-ITD
KW  - NPM1-mutation
N2  - Allogeneic transplantation (alloHCT) as post-remission therapy in patients with FLT3-ITD-positive intermediate-risk acute myeloid leukemia (AML) remains controversial. FLT3-ITD mutations are heterogeneous with respect to allelic ratio, location and length of the insertion, with a high mutant-to-wildtype ratio being consistently associated with inferior prognosis. We retrospectively analyzed the role of alloHCT in first remission in relationship to the allelic ratio and presence or absence of nucleophosmin 1 mutations (NPM1) in the SAL-AML2003 trial. FLT3-ITD mutations were detected in 209 patients and concomitant NPM1-mutations in 148 patients. Applying a pre-defined cutoff ratio of 0.8, AML was grouped into high- and low-ratio FLT3-ITD AML (HRFLT3-ITD and LRFLT3-ITD). Sixty-one patients (29%) were transplanted in first remission. Overall survival (OS) (HR 0.3, 95%CI 0.16 to 0.7, p=.004) and event-free survival (EFS) (HR 0.4, 95%CI 0.16 to 0.9, p=.02) were significantly increased in patients with HRFLT3-ITD AML who received alloHCT as consolidation treatment compared to patients who received consolidation chemotherapy. Patients with LRFLT3-ITD AML and wildtype NPM1 who received alloHCT in first remission had increased OS (HR 0.3; 95%CI 0.1 - 0.8, p=.02) and EFS (HR 0.2; 95%CI 0.1 - 0.8, p=.02) while alloHCT in first remission did not have a significant impact on OS and EFS in patients with LRFLT3-ITD AML and concomitant NPM1-mutation. In conclusion, our results provide additional evidence that alloHCT in first remission improves EFS and OS in patients with HRFLT3-ITD AML and in patients with LRFLT3-ITD AML and wildtype NPM.
ER  -

HO, A. D.; J. SCHETELIG; T. BOCHTLER; M. SCHAICH; K. SCHÄFER-ECKART; M. HÄNEL; W. RÖSLER; H. EINSELE; M. KAUFMANN; H. SERVE; W. E. BERDEL; M. STELLJES; Jiří MAYER; A. REICHLE; C. D. BALDUS; N. SCHMITZ; M. KRAMER; C. RÖLLIG; M. BORNHÄUSER; C. THIEDE a G. EHNINGER. Allogeneic stem cell transplantation improves survival in patients with AML characterized by a high allelic ratio of mutant FLT3-ITD. \textit{Biology of Blood and Marrow Transplantation}. New York: Elsevier Science INC, 2016, roč.~22, č.~3, s.~462-469. ISSN~1083-8791. Dostupné z: https://doi.org/10.1016/j.bbmt.2015.10.023.

Přehled o publikaci